acceleron pharma stock

10 Stocks to Play the Latest Innovations. The data is in, and there is no question that 2013 was the most active year for biotechnology initial public offerings since 2000. View which stocks are hot on social media with MarketBeat's trending stocks report. Acceleron Pharma is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Who Bought Acceleron Pharma? Merck confirms to acquire Acceleron in a deal valued at $11.5 billion, Merck Reportedly Close to Buying Acceleron Pharma, Merck nears deal for rare-disease-drug maker Acceleron, Acceleron Stock Is Taking Off on Reported Potential Takeover, Acceleron's stock gains 3.9% on acquisition report. Company profile page for Acceleron Pharma Inc including stock price, company news, press releases, executives, board members, and contact information MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Medicines Golden Age Is Dawning. Their stock opened with $15.00 in its Sep 19, 2013 IPO. A Merck Vet Aims To Turn That Idea Into New Medicines, Wednesday Sector Laggards: Biotechnology, Defense Stocks, Flagship Ventures, After A String Of IPOs, Gets $537M To Build More Biotech Startups, Celgene, Biotech's Ace Dealmaker, Bets On Canada's Zymeworks, Monday Sector Leaders: Insurance Brokers, Biotechnology Stocks, Biotech Analyst Optimism: Price Targets Post-IPO, Biotech IPOs: What Entrepreneurs Can Learn From A Banner Year, The Best- And Worst-Performing Biotech Stocks, Dec. 6 to Dec. 13, Venture Debt: Under-Appreciated Tool for Building Biotechs. Historical and current end-of-day data provided by FACTSET. Identify stocks that meet your criteria using seven unique stock screeners. Can Activision Blizzard Rally Into Year End? Want to see which stocks are moving? The biopharmaceutical company can be reached via phone at (617) 649-9200, via email at investor@acceleronpharma.com, or via fax at 617-649-9988. Please log in to your account or sign up in order to add this asset to your watchlist. 3 Dow Stocks That Are Screaming Buys in November. Have Watchlists? Acceleron Pharma Inc (NASDAQ:XLRN) is not the most popular stock in this group but hedge fund interest is still above average. Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. Binance confirms its backing out of deal to buy FTX assets, Biden wants to discuss Taiwan, Russia, trade with Chinas Xi at G-20 summit, Investors fear potential FTX bankruptcy spilling over to reeling crypto, stock markets, Hurricane Nicole gathers strength, forcing evacuations in Florida, Potential railroad strike delayed until early December to allow for more votes, talks, Some Republicans urge Trump to delay 2024 presidential launch after midterm disappointment, Here are the congressional seats that have flipped in the midterm elections, Rivian posts narrower quarterly loss than Wall Street feared, keeps production guidance intact, Binance CEO in internal memo: I had very little knowledge of the internal state of things at FTX, Acceleron Pharma double downgraded to market perform from strong buy at Raymond James, Merck to pay $180 per Acceleron share in cash, Merck to acquire Acceleron Pharma in deal with equity value of $11.5 bln, Merck Closes Biggest Biotech Deal of the Year, Some Acceleron Investors Want a Better Deal From Merck, Merck to Refile Notification of Acceleron Merger Deal, Extending Deadline for Shareholders. The Shares Are Up. All rights reserved. This puts Habib Dable in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. By using this site you agree to the Glassdoor gives you an inside look at what it's like to work at Acceleron Pharma, including salaries, reviews, office photos, and more. A good hint as to what happens next starts during JP Morgan's 37th Annual Healthcare Conference and the debate over the winners and losers for patients, payers and investors begins. Search job titles. What is Habib Dable's approval rating as Acceleron Pharma's CEO? Get short term trading ideas from the MarketBeat Idea Engine. Grace Capital Buys Safety Insurance Group Inc, iShares iBoxx USD Investment Grade Corporate Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move? This browser is no longer supported at MarketWatch. Cardiovascular med sotatercept passed a phase 3 test as an add-on treatment for patients with pulmonary arterial hypertension (PAH), improving patients' six-minute walk distance The average Acceleron Pharma stock forecast 2030 represents a 27.95% increase from the last price of $133.58. Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $130.07 up to $189.99. How many employees does Acceleron Pharma have? The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.18. Merck sees PAH as a roughly $7.5 billion market by 2026. Visit a quote page and your recently viewed tickers will be displayed here. Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Merck (MRK) to Report Q3 Earnings: What's in the Cards? LoginAsk is here to help you access Acceleron Pharmaceutical quickly and handle each specific case you encounter. Merck & Co. said Thursday it has agreed to acquire Acceleron Pharma Inc. in a deal with an equity value of $11.5 billion that was first reported earlier this week Merck will pay $180 in cash for each Acceleron share owne Shares of Acceleron Pharma Inc. gained 3.9% in premarket trading on Monday after Friday that an unnamed buyer is considering spending $11 billion to buy the company. The drugmaker will pay $180 per Acceleron share in cash, representing a premium of about 2.6% to the stock's closing price on. Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Pfizer (PFE), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Regeneron Pharmaceuticals (REGN). Acceleron markets one approved therapy, Reblozy, which Tesla Bull Ron Baron Drives Further Into EV Space With Rivian, Dumps Zillow, Foresite Capital Management III, LLC Buys Ascendis Pharma A/S, Natera Inc, Sells Aclaris Therapeutics Inc, , Epizyme Inc. Merck (MRK) revealed that it has completed the acquisition of Acceleron Pharma Inc. (XLRN) through its subsidiary Astros Merger Sub, Inc., in an all-cash transaction valued at $180 per share. All Rights Reserved. Copyright 2022 MarketWatch, Inc. All rights reserved. XLRN | Complete Acceleron Pharma Inc. stock news by MarketWatch. See what's happening in the market right now with MarketBeat's real-time news feed. Find the latest Acceleron Pharma Inc, XLRN stock market data. LoginAsk is here to help you access Acceleron quickly and handle each specific case you encounter. It raises financial guidance for 2021. Based in Cambridge, MA, Acceleron Pharma (XLRN) scheduled a $66 million IPO with a market capitalization of $360 million at a price range mid-point of $14 for . Merck confirms to acquire Acceleron in a deal valued at $11.5 billion, Merck Reportedly Close to Buying Acceleron Pharma, Merck nears deal for rare-disease-drug maker Acceleron, Acceleron Stock Is Taking Off on Reported Potential Takeover, Acceleron's stock gains 3.9% on acquisition report. Last month, Merck reported its most recent quarterly results. Learn why this deal is important to the biotech sector. Political Pressures Weighand What Else Is Happening in the Stock Market Today, Merck CEO Sees Multibillion-Dollar Opportunity With Acceleron. The information on this page reflects the last day Acceleron Pharma was actively traded. Do the numbers hold clues to what lies ahead for the stock? Multiple Conversion . Acceleron Pharma's revenue was up 51.6% on a year-over-year basis. Export data to Excel for your own analysis. Acceleron Pharma Inc: XLRN: NASDAQ: Common Stock Price Change Change Percent Stock Price Last Traded . Acceleron Pharma (NASDAQ:XLRN) has a market capitalization of $10.93 billion and generates $92.52 million in revenue each year. View 13F filing holders of Acceleron Pharma Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers WhaleWisdom Search All Search 13F Filers Only Search SEC Filer Search Stocks Only Search Mgmt Inv. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. But as in years past, life science investors arent as represented in the main group as that booming sector deserves. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. This screen includes biotechnology and medical companies traded on the New York Stock Exchange, the Nasdaq or the American Stock Exchange that had market capitalizations of more than $300 million as of a week ago. While the catalyst behind this double-digit jump wasn't immediately apparent (the company didn't release any material news during the week), Bloomberg News reported late Friday afternoon that the. Learn about financial terms, types of investments, trading strategies, and more. But understanding the relationship between a forecasted price target of a stock and its [], By Alex Konrad and TrueBridge Capital Partners The 2014 Midas List features the top 100 tech investors in venture capital, and this years List is a formidable group. Reblozyl is now the first and only IPO Preview: Acceleron Pharma. Working at Acceleron Pharma | Glassdoor . Acceleron Pharmaceuticals will sometimes glitch and take you a long time to try different solutions. . While the catalyst behind this double-digit jump wasn't . Biologist Nancy Thornberry, who spearheaded the development of Merck & Co.s $6 billion diabetes pill Januvia, will lead New York-based Kallyope in a quest to develop drugs [], In trading on Wednesday, biotechnology shares were relative laggards, down on the day by about 0.6%. Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Furthermore, you can find the "Troubleshooting Login Issues" section which can answer your unresolved problems and equip you . Mercks Covid Antiviral Isnt Just a Quick Win. About Acceleron Pharma Inc. [XLRN]: Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and . Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. 2022 Forbes Media LLC. Acceleron's REBLOZYL (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, Canada and Australia for the treatment of anemia in certain rare. 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The estimated base pay is $182,713 per year. Related by Industry: Drugs & Biotechnology, Located in Cambridge-Newton-Framingham, MA Metropolitan Division Metropolitan Area. Keytruda accounts for 36% of revenue. The rumored deal would value the. Stock # of Shares Authorized Par Value Dividend Rate (%) Original Issue Price Liquidation Liquidation Pref. Create a list of the investments you want to track. Acceleron Pharma Inc. is a biopharmaceutical company. For Acceleron Pharma stock forecast for 2030, 12 predictions are offered for each month of 2030 with average Acceleron Pharma stock forecast of $170.91, a high forecast of $210.66, and a low forecast of $150.89. Log in to see them here or sign up to get started. Acceleron Pharma had a negative trailing twelve-month return on equity of 32.11% and a negative net margin of 226.01%.

6th Class Syllabus 2022 Pdf, Is Peanut Butter Toast Healthy For Weight Loss, Bwf World Tour Finals 2021, The Devil's Wife Book, Dunedin Airport Weather, Crookston School Calendar, Black Female Internal Medicine Doctors Near Singapore, Outback Bloomin Shrimp Recipe, Goin' Where The Wind Blows, Mercy Hospital Pay Schedule,